Literature DB >> 30965211

Thyrotoxic periodic paralysis with ventricular tachycardia.

I-Hsun Tsai1, Yu-Jang Su2.   

Abstract

A 47-year-old man presented to our emergency department (ED) with limbs weakness for 2 h. His heart rate was 127 beats per minute and blood pressure was 95/49 mm Hg. He found weakness of limbs after 4-h sleep. Physical examinations revealed that the muscle strength of upper limbs is 3/5, and lower limbs are 2/5. Electrocardiogram (ECG) revealed wide QRS complex, monomorphic ventricular tachycardia (VT) with ST-segment depression and long QT interval. Serum potassium level was extremely low as 1.0 mEq/L. This led to periodic hypokalemic paralysis. Due to severe hypokalemia with possible atrioventricular block, the patient was admitted to the intensive care unit. During hospitalization, his potassium level returned to 5.1 mEq/L on the first day. He had a low level of thyroid stimulating hormone (TSH) of <0.03 micro-IU/mL (normal range: 0.25-4.00) and a high free thyroxine (T4) level of 2.43 ng/dL (normal range: 0.89-1.79 ng/dL). Therefore, hyperthyroidism was diagnosed, and 5 mg of methimazole was administered twice a day. The patient was discharged on the seventh day after admission. The final diagnosis is thyrotoxic periodic paralysis (TPP), also as known as nocturnal paralysis or night palsy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyperthyroidism; Hypokalemia; Paralysis

Year:  2019        PMID: 30965211     DOI: 10.1016/j.jelectrocard.2019.04.001

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  2 in total

1.  Thyrotoxic Periodic Paralysis-A Misleading Challenge in the Emergency Department.

Authors:  Stefana Bilha; Ovidiu Mitu; Laura Teodoriu; Cristian Haba; Cristina Preda
Journal:  Diagnostics (Basel)       Date:  2020-05-18

Review 2.  Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism.

Authors:  Narcis Tribulova; Lin Hai Kurahara; Peter Hlivak; Katsuya Hirano; Barbara Szeiffova Bacova
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.